Premium increase unlikely in 2015.
With all the technological setbacks and glitches of healthcare.gov at the end of 2013, and the clock ticking on open enrollment, concerns about low enrollment of the young and healthy have been abundant.
However, a recent study by the Kaiser Family Foundation (KFF) downplayed concerns that low enrollment of young adults might lead to a "death spiral.”
The study stated that under a worst-case scenario in which only 25% of enrollees are age 18 to 34, insurers would have to raise premiums by 2.5% in 2015. Similarly, if young adults represent 33% of enrollees, premiums would be raised by 1.1%.
With the addition of ACA transitional policies that allow insurers to keep premiums low as the risk pool settles in first three years, it's unlikely that premiums will increase in 2015.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Eric Levin talks PBMs and how Scripta is Tackling the Market's Challenges for Patients
July 22nd 2020MHE's Briana Contreras spoke with CEO of Scripta, Eric Levin. The two discussed the current state of the pharmacy benefit market and how the Scripta organization has been assisting its clients and their prescriptions prior to the COVID-19 pandemic and during.
Listen
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More